{"slideshow_credits": null, "snippet": "The drug maker said it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company\u2019s shares down 3 percent.", "abstract": "Merck says it will delay seeking approval for an experimental osteoporosis drug, an announcement that sends shares down 3 percent on the same day it announced its fourth-quarter earnings for 2012; fourth-quarter profit was $1.4 billion, or 46 cents a share, compared with $1.51 billion, or 49 cents a share, in year-ago quarter.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/02/business/merck-delays-osteoporosis-drug.html", "lead_paragraph": "The drug maker said it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company\u2019s shares down 3 percent.", "headline": {"seo": "Merck Delays Osteoporosis Drug", "main": "Merck Delays Osteoporosis Drug", "print_headline": "Merck Delays Application for Osteoporosis Drug"}, "_id": "510c1aff00315214fbb88a39", "word_count": "370", "multimedia": [], "pub_date": "2013-02-02T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Merck & Company Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Osteoporosis", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}